Document Type
Article
Publication Date
2013
Publication Title
BMC Cancer
Department
Geisel School of Medicine
Abstract
BackgroundHumanized KS-interleukin-2 (huKS-IL2), an immunocytokine with specificity for epithelial cell adhesion molecule (EpCAM), has demonstrated favorable tolerability and immunologic activity as a single agent.MethodsPhase 1b study in patients with EpCAM-positive advanced solid tumors to determine the maximum tolerated dose (MTD) and safety profile of huKS-IL2 in combination with low-dose cyclophosphamide. Treatment consisted of cyclophosphamide (300mg/m2 on day 1), and escalating doses of h
DOI
10.1186/1471-2407-13-20
Original Citation
Connor JP, Cristea MC, Lewis NL, Lewis LD, Komarnitsky PB, Mattiacci MR, Felder M, Stewart S, Harter J, Henslee-Downey J, Kramer D, Neugebauer R, Stupp R. A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors. BMC Cancer. 2013 Jan 15;13:20. doi: 10.1186/1471-2407-13-20. PMID: 23320927; PMCID: PMC3600662.
Dartmouth Digital Commons Citation
Connor, Joseph P.; Cristea, Mihaela C.; Lewis, Nancy L.; and Lewis, Lionel D., "A Phase 1b Study of Humanized Ks-Interleukin-2 (Huks-Il2) Immunocytokine with Cyclophosphamide in Patients with Epcam-Positive Advanced Solid Tumors" (2013). Dartmouth Scholarship. 2509.
https://digitalcommons.dartmouth.edu/facoa/2509
Comments
Connor, Joseph||Cristea, Mihaela||Lewis, Nancy||Lewis, Lionel||Komarnitsky, Philip||Mattiacci, Maria||Felder, Mildred||Stewart, Sarah||Harter, Josephine||Henslee-Downey, Jean||Kramer, Daniel||Neugebauer, Roland||Stupp, Roger